Advertisement

Dopamine D1-Receptor Binding in the Living Human Brain

  • Göran Sedvall
  • Lars Farde
  • Sharon Stone-Elander
  • Christer Halldin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)

Abstract

The neurotransmitter dopamine, which plays a role in the pathophysiology of Parkinson’s Disease and possibly also schizophrenia, mediates its actions in the brain by at least two types of receptors (Kebabian and Calne, 1979). By the activation of the dopamine D1 receptor, dopamine stimulates the enzyme adenylate cyclase (Kebabian et al., 1972). Activation of the dopamine D2 receptor is not, or is possibly negatively, coupled to a dopamine sensitive adenylate cyclase (Stoof and Kebabian, 1984). Many behavioural effects of dopamine seem to be mediated by D2 receptors (Peroutka and Snyder, 1980). The analysis of D2 receptors has been facilitated by the availability of selective drugs interacting with this receptor. The exploration of dopamine D1 receptor characteristics and function has been hampered by the previous lack of such pharmacological tools.

Keywords

Positron Emission Tomography Dopamine Receptor Adenylate Cyclase Neocortical Area Caudate Putamen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dawson, T.M., Gehlert, D.R., Yamamura, H.I., Barnett, A. and Wamsley, J.K., 1985, D1 dopamine receptors in the rat brain: Autoradiographic localization using 3H SCH 23390, Eur. J. Pharmacol., 108:323–325.PubMedCrossRefGoogle Scholar
  2. Farde, L., Ehrin, E., Eriksson, L., Greitz, T., Hall, H. Hedstrom, CG., Litton, J-E. and Sedvall, G., 1985, Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography, Proc. Natl. Acad. Sci., 82:3863.PubMedCrossRefGoogle Scholar
  3. Farde, L., Hall, H., Ehrin, E. and Sedvall, G., 1985, Quantitative analysis of dopamine D2 receptor binding in the living human brain by PET, Science, 231:258.CrossRefGoogle Scholar
  4. Flaim, K.E., Gessner, G.W., Crooke, S.T., Sarau, H.M., and Weinstock, J., 1985, Binding of a noval dopaminergic agonist radioligand 3H-fenlodopam (SKF 82526) to D1 receptors in rat striatum, Life Sci., 36:1427–1436.PubMedCrossRefGoogle Scholar
  5. Friedman, A., Dejesus, O.T., Woolverton, W.L., van Moffaert, G., Goldberg, L.I., Prasad, A., Barnett, A. and Dinerstein, R., 1985, Positron tomography of radio-brominated analog of the D1/DA1 antagonist, SCH 23390, Eur. J. Pharmacol. 108:327.PubMedCrossRefGoogle Scholar
  6. Halldin, C., Stone-Elander, S., Farde, L., Ehrin, E., Fasth, K.J., Langstrom, B. and Sedvall, G., 1986, Preparation of 11C labelled SCH 23390 for the in vivo analysis of dopamine D1 receptors by positron emission tomography, J. Appl. Radiochem. Isotop, In press.Google Scholar
  7. Hicks, P.E., Schoemaker, H. and Langer, S.Z., 1984, 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain, Eur. J. Pharmacol., 105:339–342.PubMedCrossRefGoogle Scholar
  8. Hyttel, I., 1984, Functional evidence of selective dopamine D1 receptor blockade by SCH 23390, Neuropharmacol., 23:1395–1401.CrossRefGoogle Scholar
  9. Iorio, L.C., Barnett, A., Leitz, F.H., Houser, V.P., Korduba, C.A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ther., 226:462–468.PubMedGoogle Scholar
  10. Kebabian, J.W. and Calne, D.B., 1979, Multiple receptors for dopamine, Nature 277:93–96.PubMedCrossRefGoogle Scholar
  11. Kebabian, J.W., Petzold, G.L. and Greengard, P., 1972, Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”, Proc. Nat. Acad. Sci., 69, No. 8, 2145–2149.PubMedCrossRefGoogle Scholar
  12. Peroutka, S.J. and Snyder, S.H., 1980, Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency, Am. J. Psychiatry 173:12, 1518–1522.Google Scholar
  13. Raisman, R., Cash, R., Ruberg, M., Javoy-Agid, F. and Agid, Y., 1985, Binding of H3-SCH 23390 to D1 receptors in the putamen of control and parkinsonian subjects, Eur. J. Pharmacol., 113:467.PubMedCrossRefGoogle Scholar
  14. Sedvall, G., Blomqvist, G., dePaulis, S., Ehrin, E., Eriksson, L., Farde, L., Greitz, T. Hedstrom, C.G., Ingvar, D.H., Litton, J.E., Nilsson, J.L.G., Stone-Elander, S., Widen, L., Wiesel, F.A. and Wik, G., 1983, 11-C-labelled benzamides as ligands for imaging of dopamine receptors in the human brain, 1983 ACNP Annual Meeting, San Juan, December 12–16.Google Scholar
  15. Stoof, J.C and Kebabian, J.W., 1984, Two dopamine receptors: Biochemistry, physiology and pharmacology, Life Sci., 35:2281–2296.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Göran Sedvall
    • 1
  • Lars Farde
    • 1
  • Sharon Stone-Elander
    • 2
  • Christer Halldin
    • 2
  1. 1.Department of Psychiatry, PsychologyKarolinska HospitalStockholmSweden
  2. 2.Department of Psychiatry, PharmacyKarolinska HospitalStockholmSweden

Personalised recommendations